Bristol-Myers preps second checkpoint/cancer vax combo study under its $1B Bavarian Nordic pact
Bristol-Myers Squibb is ready to launch its second combination trial using Bavarian Nordic’s cancer vaccine Prostvac.
Operating under a 2015 deal worth up to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.